Dosimetric uncertainty in prostate cancer proton radiotherapy

2008 ◽  
Vol 35 (11) ◽  
pp. 4800-4807 ◽  
Author(s):  
Liyong Lin ◽  
Carlos Vargas ◽  
Wen Hsi ◽  
Daniel Indelicato ◽  
Roelf Slopsema ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Proton Radiotherapy

Proton radiotherapy for prostate cancer in the Medicare population: Patterns of care and comparison of early toxicity with IMRT.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. 4651-4651
Author(s):  
James B. Yu ◽  
Pamela R. Soulos ◽  
Laura D. Cramer ◽  
Kenneth B Roberts ◽  
Jeph Herrin ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Logistic Regression ◽  
Cancer Patients ◽  
Post Treatment ◽  
Complication Rates ◽  
Proton Radiotherapy ◽  
Short Term ◽  
Significant Difference ◽  
Patient Reported ◽  
One Year

4651 Background: Proton radiotherapy (PRT) is a costly treatment used for prostate cancer despite little evidence supporting its use. We examined patterns of PRT use in the Medicare program and assessed the short-term toxicity of PRT vs. intensity modulated radiation therapy (IMRT). Methods: Using national Medicare claims from 2008-2009, we identified a sample of prostate cancer patients ages 66-94 who had received PRT or IMRT. We used multivariable logistic regression to identify patient and regional factors associated with receipt of PRT. We searched claims for procedure and diagnosis codes indicative of treatment-related complications and grouped the complications into genitourinary (GU), gastrointestinal (GI), and other complications. To compare the effect of PRT and IMRT on short-term toxicity, we used a Mahalanobis distance approach to match each PRT patient to two IMRT patients, achieving balanced distribution of clinical and sociodemographic characteristics. We compared six-month and one-year outcomes between the two treatment groups using conditional logistic regression. Results: We identified 27,647 men; 421 (2%) received PRT and 27,226 (98%) received IMRT. Patients who received PRT were widely geographically distributed, with some patients traveling >500 miles for treatment. PRT patients were younger, healthier, and of higher socioeconomic status. Although PRT was associated with a significant reduction in GU complications at six-months compared with IMRT (6.1% vs. 12.0%, OR 0.60 [95% CI 0.38-0.96], p=0.03), at one-year post-treatment there was no longer any difference in cumulative complication rates (18.9% vs. 21.9%, OR 0.96 [95% CI 0.61-1.53], p=0.88). There was no significant difference in GI or other complications at six-months or one-year post-treatment. Conclusions: Although PRT remains a scarcely used treatment, some prostate cancer patients traveled great distances for treatment. While PRT was associated with a reduction in six-month GU toxicity, there were no differences in toxicity at one-year. Further study on longer-term effects and other clinical and patient-reported outcomes is needed to inform the widespread application of PRT.

Dosimetric Study of Pelvic Proton Radiotherapy for High-Risk Prostate Cancer

2009 ◽  
Vol 75 (4) ◽  
pp. 994-1002 ◽  
Author(s):  
Bhishamjit S. Chera ◽  
Carlos Vargas ◽  
Christopher G. Morris ◽  
Debbie Louis ◽  
Stella Flampouri ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
High Risk ◽  
Proton Radiotherapy ◽  
High Risk Prostate Cancer ◽  
Risk Prostate Cancer ◽  
Dosimetric Study

Equivalent dose and effective dose from stray radiation during passively scattered proton radiotherapy for prostate cancer

2008 ◽  
Vol 53 (6) ◽  
pp. 1677-1688 ◽  
Author(s):  
Jonas Fontenot ◽  
Phillip Taddei ◽  
Yuanshui Zheng ◽  
Dragan Mirkovic ◽  
Thomas Jordan ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Effective Dose ◽  
Equivalent Dose ◽  
Proton Radiotherapy ◽  
Scattered Proton ◽  
Stray Radiation

Proton Radiotherapy for Prostate Cancer is Not Associated with Post Treatment Testosterone Suppression

2009 ◽  
Vol 75 (3) ◽  
pp. S344-S345
Author(s):  
R. Nichols ◽  
C.G. Morris ◽  
B.G. Hoppe ◽  
R.H. Henderson ◽  
R.M. Marcus ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Post Treatment ◽  
Proton Radiotherapy

Proton Radiotherapy for Prostate Cancer Is Not Associated With Post-Treatment Testosterone Suppression

2012 ◽  
Vol 82 (3) ◽  
pp. 1222-1226 ◽  
Author(s):  
R. Charles Nichols ◽  
Christopher G. Morris ◽  
Bradford S. Hoppe ◽  
Randal H. Henderson ◽  
Robert B. Marcus ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Post Treatment ◽  
Proton Radiotherapy

Influence of patient age on biochemical freedom from disease in patients undergoing conformal proton radiotherapy of organ-confined prostate cancer

Urology ◽  
2004 ◽  
Vol 64 (4) ◽  
pp. 729-732 ◽  
Author(s):  
Carl J. Rossi ◽  
Jerry D. Slater ◽  
Les T. Yonemoto ◽  
B. Rodney Jabola ◽  
David A. Bush ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Proton Radiotherapy ◽  
Patient Age ◽  
Patient Âgé ◽  
Freedom From Disease

scholarly journals Hypofractionated passively scattered proton radiotherapy for low- and intermediate-risk prostate cancer is not associated with post-treatment testosterone suppression

2013 ◽  
Vol 52 (3) ◽  
pp. 492-497 ◽  
Author(s):  
Whoon Jong Kil ◽  
Romaine C. Nichols ◽  
Bradford S. Hoppe ◽  
Christopher G. Morris ◽  
Robert B. Marcus ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Post Treatment ◽  
Intermediate Risk ◽  
Proton Radiotherapy ◽  
Scattered Proton ◽  
Risk Prostate Cancer
Sign in / Sign up

Export Citation Format

Share Document